NEW YORK (GenomeWeb News) – Invetech will support the development and manufacture of Biocartis' multiplex platform for biomarker analysis under an agreement announced today.
Invetech will support the development of Biocartis' Evaluation instrument for analyzing protein and nucleic acid-based biomarkers to support clinical research and pharmaceutical applications, the partners said. Evaluation "provides an integrated reaction and detection environment," while enabling the simultaneous investigation of multiple analytes per sample, the companies added.
The platform reduces hands-on time and development complexity and could streamline biomarker validation and verification, Biocartis and Invetech said. Evaluation also "offers real-time visualization of the reaction and data traceability for easy and reliable assay development," they said.
Financial and other terms of the deal were not disclosed.
Belgium-based Biocartis also is developing the Idylla molecular diagnostic platform and plans to launch it in the second half of the year. Late last year, the firm raised $40.5 million to validate and continue assay development for the system.